CN111297916A - 一种防治免疫过激产生巨量自由基引起器官损伤的方法 - Google Patents
一种防治免疫过激产生巨量自由基引起器官损伤的方法 Download PDFInfo
- Publication number
- CN111297916A CN111297916A CN202010099866.8A CN202010099866A CN111297916A CN 111297916 A CN111297916 A CN 111297916A CN 202010099866 A CN202010099866 A CN 202010099866A CN 111297916 A CN111297916 A CN 111297916A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- astaxanthin
- haematococcus pluvialis
- administered
- daily dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 230000008816 organ damage Effects 0.000 title claims abstract description 12
- 150000003254 radicals Chemical class 0.000 title claims description 21
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 18
- 241000168517 Haematococcus lacustris Species 0.000 claims description 18
- 235000013793 astaxanthin Nutrition 0.000 claims description 18
- 239000001168 astaxanthin Substances 0.000 claims description 18
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 18
- 229940022405 astaxanthin Drugs 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- OENHQHLEOONYIE-UKMVMLAPSA-N beta-Carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 5
- 241001122767 Theaceae Species 0.000 claims description 5
- 235000010208 anthocyanin Nutrition 0.000 claims description 5
- 239000004410 anthocyanin Substances 0.000 claims description 5
- 229930002877 anthocyanin Natural products 0.000 claims description 5
- 150000004636 anthocyanins Chemical class 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 5
- 235000012661 lycopene Nutrition 0.000 claims description 5
- 239000001751 lycopene Substances 0.000 claims description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 5
- 229960004999 lycopene Drugs 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 208000013403 hyperactivity Diseases 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 230000006378 damage Effects 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 230000036039 immunity Effects 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023644 Lacrimation increased Diseases 0.000 description 3
- 206010028748 Nasal obstruction Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000036071 Rhinorrhea Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004317 lacrimation Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开的是一种防治免疫过激产生巨量自由基引起器官损伤的方法，本发明的目的在于提供一种能有效预防和治疗人体免疫过激反应产生大量自由基从而导致器官损伤的方法。该方法主要通过口服或含服一定剂量通常高于保健剂量的雨生红球藻虾青素、或维生素C、或维生素E、或β胡萝卜素、或辅酶Q、或番茄红素、或花青素、或茶多酚、或它们的组合，从而实现对微生物入侵，特别是病毒入侵引起的免疫过激反应产生大量过氧化自由基的清理，起到预防和治疗因自由基引起的器官损伤的作用。本发明效果明显、无需处方、实现方便，可预防和治疗人体免疫过激反应引起的器官损伤，对维护人们的生命和器官健康大有益处。
Description
技术领域
本发明涉及一种防治免疫过激产生巨量自由基引起器官损伤的方法， 属于食品、保健食品、生物制药等领域。
技术背景
免疫系统具有免疫监视、防御、调控的作用，它由免疫器官、免疫 细胞以及免疫活性物质组成，是机体执行免疫应答及免疫功能的重要系统， 具有识别和排除抗原性异物、与机体其他系统相互协调.共同维持机体内环 境稳定和生理平衡的功能。
免疫系统是防卫病原体入侵最有效的武器，它能发现并清除异物、外 来病原微生物等引起内环境波动的因素,但其功能的亢进会对自身器官或组 织产生伤害。当某些传染性强危害大的病原微生物进入人体后引起机体免疫 亢进和过激反应，由此产生巨量有害自由基，特别是过氧化自由基，它们将 对人体器官产生毁灭性不可逆转的伤害，导致身体健康受到极大的威胁，甚 至死亡。
上述可见，抑制自由基可以抑制病毒的增殖，同时也可以避免免 疫系统的过激反应，从而抑制炎症的产生，减少毒血症状和器官损伤。
本发明的一种防治免疫过激产生巨量自由基引起器官损伤的方法，可 有效清除免疫过激反应所产生的大量自由基，特别是过氧化自由基，阻止它 们对细胞、器官的损伤，同时可减轻炎症和通过防止脂质过氧化反应来保护 细胞膜和DNA，对免疫过激反应造成器官损伤的患者是个巨大的福音。
发明内容
本发明的目的在于为由外来微生物的入侵，特别是病毒入侵造成自身 免疫过激反应引起器官损伤的患者带来具有预防和治疗效果的方法。
一种防治免疫过激产生巨量自由基引起器官损伤的方法，该方法主要 通过口服或含服一定剂量通常高于保健剂量的雨生红球藻虾青素、或维生素C、 或维生素E、或β胡萝卜素、或辅酶Q10、或番茄红素、或花青素、或茶多酚、 或它们的组合。
一种防治免疫过激产生巨量自由基引起器官损伤的方法,所述的雨生 红球藻虾青素包括水溶雨生红球藻虾青素、雨生红球藻破壁孢子粉、雨生红 球藻虾青素油。
一种防治免疫过激产生巨量自由基引起器官损伤的方法,所述的雨生 红球藻虾青素每日剂量为1-100mg。
一种防治免疫过激产生巨量自由基引起器官损伤的方法，所述的维生 素C每日服用剂量为0.01-30g、维生素E每日服用剂量为1-400mg、β胡萝 卜素每日服用剂量为1-1200mg、辅酶Q10每日服用剂量为1-1000mg、番茄红 素每日服用剂量为1-500mg、花青素每日服用剂量为10-3000mg、茶多酚每日 服用剂量为1-800mg。
一种防治免疫过激产生巨量自由基引起器官损伤的方法，作为优选的 组合为水溶雨生红球藻虾青素每日服用剂量为8-24mg、维生素C每日服用剂 量为1-5g、维生素E每日服用剂量为10-50mg。
具体实施方式:
以下通过具体的实施方式对本发明作进一步的说明，但本发明的实施方 式并不受以下实施例的限制。
实施例1 2020年2月2日，柳某，56岁，出现发烧，喉咙痛，每日大剂 量含服水溶雨生红球藻虾青素36mg，服用两天，烧退，喉咙疼痛消失。出现 发烧为病毒引起的免疫过激反应，服用水溶虾青素除可以保护黏膜及呼吸道 外，还可清除大量的有害自由基和减轻炎症，从而保护细胞和呼吸道系统。
实施例2 2019年12月5日，王某，45岁，出现鼻塞、流鼻涕、流泪等 症状，每日含服水溶雨生红球藻虾青素12mg，服用一天，鼻塞、流鼻涕、流 泪等症状消失。出现鼻塞、流鼻涕、流泪等症状为外来微生物入侵导致的机 体免疫反应，服用水溶虾青素可清除大量的有害自由基和消除症状。
实施例3一种防治免疫过激产生巨量自由基引起器官损伤的方法，该方 法主要通过每日饭后半小时口服或含服6-24mg水溶雨生红球藻虾青素。
实施例4一种防治免疫过激产生巨量自由基引起器官损伤的方法，该方 法主要通过每日饭后半小时口服或含服6-12mg水溶雨生红球藻虾青素、1g维 生素C、40mg维生素E。
实施例5一种防治免疫过激产生巨量自由基引起器官损伤的方法，该方 法主要通过每日饭后半小时口服或含服4mg水溶雨生红球藻虾青素、1g维生 素C、40mg维生素E、500mgβ-胡萝卜素、100mg辅酶Q10、50mg番茄红素、 600mg花青素、200mg茶多酚。
Claims (5)
1.一种防治免疫过激产生巨量自由基引起器官损伤的方法，其特征在于，该方法主要通过口服或含服一定剂量通常高于保健剂量的雨生红球藻虾青素、或维生素C、或维生素E、或β胡萝卜素、或辅酶Q10、或番茄红素、或花青素、或茶多酚、或它们的组合。
2.根据权利要求1所述的一种防治免疫过激产生巨量自由基引起器官损伤的方法，其特征在于，所述的雨生红球藻虾青素包括水溶雨生红球藻虾青素、雨生红球藻破壁孢子粉、雨生红球藻虾青素油。
3.根据权利要求1所述的一种防治免疫过激产生巨量自由基引起器官损伤的方法，其特征在于，所述的雨生红球藻虾青素每日剂量为1-100mg。
4.根据权利要求1所述的一种防治免疫过激产生巨量自由基引起器官损伤的方法，其特征在于，所述的维生素C每日服用剂量为0.01-30g、维生素E每日服用剂量为1-400mg、β胡萝卜素每日服用剂量为1-1200mg、辅酶Q10每日服用剂量为1-1000mg、番茄红素每日服用剂量为1-500mg、花青素每日服用剂量为10-3000mg、茶多酚每日服用剂量为1-800mg。
5.根据权利要求1所述的一种防治免疫过激产生巨量自由基引起器官损伤的方法，其特征在于，作为优选的组合为水溶雨生红球藻虾青素每日服用剂量为8-24mg、维生素C每日服用剂量为1-5g、维生素E每日服用剂量为10-50mg。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010099866.8A CN111297916A (zh) | 2020-02-18 | 2020-02-18 | 一种防治免疫过激产生巨量自由基引起器官损伤的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010099866.8A CN111297916A (zh) | 2020-02-18 | 2020-02-18 | 一种防治免疫过激产生巨量自由基引起器官损伤的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111297916A true CN111297916A (zh) | 2020-06-19 |
Family
ID=71151061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010099866.8A Pending CN111297916A (zh) | 2020-02-18 | 2020-02-18 | 一种防治免疫过激产生巨量自由基引起器官损伤的方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111297916A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112691092A (zh) * | 2021-02-05 | 2021-04-23 | 云南维他源生物科技有限公司 | 一种治疗缺血性心脏病的药物组合物及其制剂与应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102356874A (zh) * | 2011-09-23 | 2012-02-22 | 北京康比特体育科技股份有限公司 | 一种抗氧化保健食品组合物及其制备方法和应用 |
| CN103110111A (zh) * | 2012-12-03 | 2013-05-22 | 郭威 | 一种复合抗氧化营养食品及其加工方法 |
| CN110237105A (zh) * | 2019-07-05 | 2019-09-17 | 湖北真福医药有限公司 | 一种强效抗氧化软胶囊及其制备方法 |
-
2020
- 2020-02-18 CN CN202010099866.8A patent/CN111297916A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102356874A (zh) * | 2011-09-23 | 2012-02-22 | 北京康比特体育科技股份有限公司 | 一种抗氧化保健食品组合物及其制备方法和应用 |
| CN103110111A (zh) * | 2012-12-03 | 2013-05-22 | 郭威 | 一种复合抗氧化营养食品及其加工方法 |
| CN110237105A (zh) * | 2019-07-05 | 2019-09-17 | 湖北真福医药有限公司 | 一种强效抗氧化软胶囊及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 沈云辉等: "抗氧化应激研究进展", 《中成药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112691092A (zh) * | 2021-02-05 | 2021-04-23 | 云南维他源生物科技有限公司 | 一种治疗缺血性心脏病的药物组合物及其制剂与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chan et al. | Amauroderma rugosum (Blume & T. Nees) Torrend: Nutritional Composition and Antioxidant and Potential Anti‐Inflammatory Properties | |
| EP2285218B1 (en) | Dietary compositions and methods for protection against chemotherapy or radiotherapy | |
| Serkedjieva | Antioxidant effects of plant polyphenols: a case study of a polyphenol-rich extract from Geranium sanguineum L | |
| US9943503B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| CN111297916A (zh) | 一种防治免疫过激产生巨量自由基引起器官损伤的方法 | |
| Tripathi et al. | Role of Rubia cordifolia Linn. in radiation protection | |
| Yaqoob et al. | Mechanistic role of astaxanthin derived from shrimp against certain metabolic disorders | |
| US20150196614A1 (en) | Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith | |
| Oliveira et al. | Pre-treatment with glutamine reduces genetic damage due to cancer treatment with cisplatin | |
| US20190247360A1 (en) | Pharmaceutical Composition for Treating Bacterial and Viral infections | |
| Ajayi et al. | The hepatoprotective properties of methanolic extract of Garcinia kola administration on azathioprine-induced liver toxicity of adult sprague-dawley rats | |
| Hassan et al. | Wheat Grass (Triticum aestivum L.) Benefits Health in a Pandemic Scenario | |
| CA2346647C (en) | Treatment of dyspepsia | |
| Verma et al. | Quercetin 3 Rutinoside Facilitates Protection Against Radiation Induced Genotoxic and Oxidative Damage A Study in C57bl 6 Mice | |
| Verma et al. | Role of Spinacia oleracea as Antioxidant: A biochemical study on mice brain after exposure of gamma radiation | |
| CN102580065A (zh) | 虎眼万年青皂甙osw-i口服抗癌制剂及其制备方法 | |
| Ali et al. | Immunogenetic disorders: Treatment with phytomedicines | |
| US20130196934A1 (en) | Composition for perinatal and neonatal stroke | |
| CN104622861B (zh) | E-10-羟基-2-癸烯酸在防治化学肝损伤的药物中的应用 | |
| Rastogi et al. | Pycnogenol: the hercules of antioxidants | |
| El-Said et al. | Synergistic effect of avenanthramides and cisplatin co-treatment in Ehrlich ascites carcinoma-bearing mice | |
| Jose et al. | REVIEW ON CNIDOSCOLUS ACONITIFOLIUS (CHAYAMANSA)-A TRADITIONAL MEDICINAL PLANT | |
| US10532075B2 (en) | Use of a particular extract of propolis for combating the side effects of chemotherapy | |
| Indrawati et al. | Humans’ Body Immunity and Natural Pigments | |
| US20220257640A1 (en) | Nutritional formulation for cancer prevention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200619 |